



April 30, 2020

Paladin Labs Inc.  
100 Alexis Nihon Blvd., Suite 600  
St. Laurent, Quebec, Canada H4M 2P2

**Healthcare Professional Information regarding discontinuation of XIAFLEX®**

Dear Healthcare Professional:

We are writing to inform you that Paladin will discontinue the commercialization of XIAFLEX® (collagenase clostridium histolyticum) in Canada as of June 30, 2020.

The decision to withdraw is not based on safety or efficacy concerns. Despite best efforts to appropriately educate the government and the market on XIAFLEX® over the past several years, the product did not receive government reimbursement approval and demand for the product has remained unsustainably low.

Please be assured that the wellbeing of patients during the discontinuation process is of paramount importance to Paladin and we are committed to the safety and comfort of all patients during the process of transition to other therapies. We want to emphasize that subject to product availability, Paladin is committed to providing XIAFLEX® up until June 30, 2020 for completion of on-going treatment. However, as of today, there will be no further certification of new doctors regarding the use and administration of XIAFLEX®.

For inquiries regarding XIAFLEX® please contact:

[medinfo@paladinlabs.com](mailto:medinfo@paladinlabs.com) or 1-888-867-7426

We would like to thank you for your interest in XIAFLEX® and regret any inconvenience this may cause you. If you have any questions or concerns, please do not hesitate to contact us.

Yours Sincerely,

Livio Di Francesco  
General Manager